| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/03/2011 | US20110052588 Method of treating hepatocellular carcinoma |
| 03/03/2011 | US20110052587 Peptide or protein comprising a c'-d loop of the cd28 receptor family |
| 03/03/2011 | US20110052586 Antibodies to an epitope of agr2, assays and hybridomas |
| 03/03/2011 | US20110052585 Compositions and methods for inhibiting interleukin pathways |
| 03/03/2011 | US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses |
| 03/03/2011 | US20110052583 Pyridinone compounds |
| 03/03/2011 | US20110052582 Humanized Anti-CDCP1 Antibodies |
| 03/03/2011 | US20110052581 Use of picoplatin and cetuximab to treat colorectal cancer |
| 03/03/2011 | US20110052580 Use of picoplatin and bevacizumab to treat colorectal cancer |
| 03/03/2011 | US20110052579 Ligands of the Natural Killer (NK) Cell Surface Marker CD27 and Therapeutic Uses Thereof, |
| 03/03/2011 | US20110052578 Compounds and Compositions as Protein Kinase Inhibitors |
| 03/03/2011 | US20110052577 Antibodies |
| 03/03/2011 | US20110052576 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| 03/03/2011 | US20110052575 Anti-vegf antibodies |
| 03/03/2011 | US20110052574 Method of inhibition of leukemic stem cells |
| 03/03/2011 | US20110052573 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis |
| 03/03/2011 | US20110052572 Regulators of mmp-9 and uses therof |
| 03/03/2011 | US20110052571 Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies |
| 03/03/2011 | US20110052570 Method to prognose response to anti-egfr therapeutics |
| 03/03/2011 | US20110052569 Molecules and methods for treatment of diabetes |
| 03/03/2011 | US20110052568 Tablet comprising natural allicin and method for producing the same |
| 03/03/2011 | US20110052567 Methods Compositions, Uses, and Kits Useful for Vitamin D Deficiency and Related Disorders |
| 03/03/2011 | US20110052566 Cognitive function |
| 03/03/2011 | US20110052565 Non-aggregating human vh domains |
| 03/03/2011 | US20110052564 Enhancement of immunogenicity of antigens |
| 03/03/2011 | US20110052563 Gonadal function improving agents |
| 03/03/2011 | US20110052535 Compositions for treating an inflammatory autoimmune condition |
| 03/03/2011 | US20110052529 Methods and compositions for expanding t regulatory cells |
| 03/03/2011 | US20110052527 Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| 03/03/2011 | US20110052525 Breaking Immunological Tolerance with a Genetically Encoded Unnatural Amino Acid |
| 03/03/2011 | US20110052501 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| 03/03/2011 | US20110052500 TAJ in Neuronal Function |
| 03/03/2011 | US20110052498 Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders |
| 03/03/2011 | US20110052496 Hollow nanoparticles and uses thereof |
| 03/03/2011 | US20110052493 Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1 |
| 03/03/2011 | US20110052489 Anti-CD19 Antibodies |
| 03/03/2011 | US20110052488 Methods For Treating, Diagnosing, and Monitoring Rheumatoid Arthritis |
| 03/03/2011 | CA2808867A1 Methods for treating conditions mediated by the inflammatory cytokine cascade using gapdh inhibitors |
| 03/03/2011 | CA2772551A1 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 03/03/2011 | CA2772380A1 Methods of treatment using anti-oxidized ldl antibodies |
| 03/03/2011 | CA2772379A1 Antibodies that bind tau oligomers |
| 03/03/2011 | CA2772104A1 Hybrid polypeptides including meningococcal fhbp sequences |
| 03/03/2011 | CA2772103A1 Adjuvant comprising aluminium, oligonucleotide and polycation |
| 03/03/2011 | CA2771781A1 Antikine antibodies that bind to multiple cc chemokines |
| 03/03/2011 | CA2771672A1 Means and methods for producing artificial capsular polysaccharides of neisseria meningitidis |
| 03/03/2011 | CA2771328A1 Cofactors for thrombin activation of factor vii and uses thereof |
| 03/03/2011 | CA2771186A1 Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| 03/03/2011 | CA2770173A1 Velocity factor |
| 03/03/2011 | CA2770161A1 Humanized anti-cdcp1 antibodies |
| 03/03/2011 | CA2770141A1 Antibodies against cdcp1 for the treatment of cancer |
| 03/02/2011 | EP2290366A1 Analysis of saccharide vaccines without interference |
| 03/02/2011 | EP2290109A2 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| 03/02/2011 | EP2290108A2 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| 03/02/2011 | EP2290104A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 03/02/2011 | EP2290103A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 03/02/2011 | EP2290083A1 Conserved neisserial antigens |
| 03/02/2011 | EP2290082A1 Streptococcus pyogenes antigens |
| 03/02/2011 | EP2290081A2 IL-17 homologous polypeptide and therapeutic uses thereof |
| 03/02/2011 | EP2290077A2 Natural IGM antibodies and inhibitors thereof |
| 03/02/2011 | EP2290055A2 Polymorphisms in the human gene for cytochrome P450 polypeptide 2C8 and their use in diagnostic and therapeutic applications |
| 03/02/2011 | EP2290053A1 Method for producing Influenza virus in protein-free cell culture medium |
| 03/02/2011 | EP2289944A2 Bispecific antibody substituting for functional proteins |
| 03/02/2011 | EP2289942A2 Anti-HER2 antibody variants |
| 03/02/2011 | EP2289941A2 Administration of agents for the treatment of inflammation |
| 03/02/2011 | EP2289940A2 Treatment of metastatic disease |
| 03/02/2011 | EP2289938A2 Use of Panton-Valentine Leukocidin for treating and preventing staphylococcus infections |
| 03/02/2011 | EP2289936A1 Immunoglobulin variants and uses thereof |
| 03/02/2011 | EP2289935A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289934A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289933A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289932A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289931A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289930A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289929A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289928A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289927A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289926A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289925A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289924A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289923A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289922A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289921A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289920A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289919A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289918A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289917A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289916A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289915A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289914A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289913A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289912A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289910A2 Differential in tumour gene products and use of same |
| 03/02/2011 | EP2289907A2 Streptococcus agalactiae antigens I + II |
| 03/02/2011 | EP2289599A2 Compositions comprising neisseria meningitidis antigens from serogroups B and C |
| 03/02/2011 | EP2289559A1 Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| 03/02/2011 | EP2289552A1 An immunosuppressive agent plus anti-TCR antibodies for the induction of chimerism in transplantation |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289550A2 Ultra high affinity neutralizing antibodies |
| 03/02/2011 | EP2289549A2 Immunoconjugates for treating cancer |
| 03/02/2011 | EP2289548A2 Combined vaccines comprising hepatitis B surface antigen and other antigens |